For Lyft, and eager investors and traders, the wait is finally over, and after weeks of optimistic chatter about their plans, Lyft has finally filed for IPO and has gone public, meaning part of this company ride hail company is available for investors to buy. Lyft made their public offering known in the last week of March along with Genfit, and Precision Bioscience, both of which are biotech companies.
With shares priced at a range of $70-$72, and with over 32.5 million shares sold, Lyft was able to acquire upwards of $2.3 billion on its debut. The values indicate a positive IPO not just for Lyft but for the other companies that made their debut with it, including 8i Enterprises Acquisition, a blank cheque company from Asia.
Both biotech companies enjoyed a productive week as well, with Precision Bioscience starting its debut with a 9% gain before ending the week with a comfortable 12% from its initial public offering. Likewise, on its debut day, Genfit acquire a 9%, before closing the week with a high 18% gain on its IPO